- Molecular NameRanitidine
- SynonymRanitidine Base; Ranitidine HCL; Ranitidine hydrochloride; Rantidine HCL
- Weight301.371
- Drugbank_IDDB00863
- ACS_NO66357-35-5
- Show 2D model
- LogP (experiment)0.27
- LogP (predicted, AB/LogP v2.0)0.32
- pka2.3, 8.2
- LogD (pH=7, predicted)-1.92
- Solubility (experiment)24.7 mg/ml
- LogS (predicted, ACD/Labs)(ph=7)-0.55
- LogSw (predicted, AB/LogsW2.0)3.98
- Sw (mg/ml) (predicted, ACD/Labs)1.19
- No.of HBond Donors3
- No.of HBond Acceptors8
- No.of Rotatable Bonds10
- TPSA135.72
- StatusFDA approved
- AdministrationOral, IV
- PharmacologyA histamine H2-receptor antagonist that inhibits stomach acid production. It is commonly used in treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). Ranitidine is also used alongside fexofenadine and other antihistamines for the treatment of skin conditions such as hives.
- Absorption_value57.0
- Absorption (description)N/A
- Caco_2-6.31
- Bioavailability52.0
- Protein binding15.0
- Volume of distribution (VD)1.3 L/kg
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmHepatic. Ranitidine is metabolized to the N-oxide, S-oxide, and N-desmethyl metabolites, accounting for approximately 4%, 1%, and 1% of the dose, respectively.
- Half life2.8~3.1 h
- Excretion30–70% Renal
- Urinary Excretion69
- Clerance10.4 ml/min/kg
- ToxicitySymptoms of overdose include muscular tremors, vomiting, and rapid respiration.
- LD50 (rat)N/A
- LD50 (mouse)LD50=77 mg/kg